Please login to the form below

Not currently logged in
Email:
Password:

Sir John Bell

This page shows the latest Sir John Bell news and features for those working in and with pharma, biotech and healthcare.

AI company Sensyne raises £60m in IPO

AI company Sensyne raises £60m in IPO

It also has a high-profile board, including NHS England’s Sir Bruce Keogh and eminent immunologist and geneticist Professor Sir John Bell, who will serve as non-executive chairman.

Latest news

  • Brexit rebels win vote on European Medicines Agency alignment Brexit rebels win vote on European Medicines Agency alignment

    EMA membership will be a key negotiating aim; Sir John Bell sees independent MHRA post-Brexit. ... Sir John Bell, life sciences leader and author of the UK life sciences industrial strategy report said the UK's current proposal for the UK to be an EMA

  • UK trumpets life sciences post-Brexit ‘sector deal’ UK trumpets life sciences post-Brexit ‘sector deal’

    The sector deal follows the UK’s industrial strategy white paper – drawn up by geneticist Sir John Bell – which pledged a series of new R&D investments. ... As laid out in Sir John’s paper, the sector deal focuses on key themes including

  • NICE: We're the institute of 'yes' NICE: We're the institute of 'yes'

    s position for the good of the country, and that's what Sir John Bell clearly indicates.". ... In which case I think there's a fantastic future. If we fail to respond to it we're going to have some hard times and the Sir John Bell report

  • UK life sciences sector sets out its post-Brexit growth proposals UK life sciences sector sets out its post-Brexit growth proposals

    Review helmed by Sir John Bell outlines a wide-ranging strategy. The UK life sciences industry has set out a strategy for making the country a ‘world leader’ in the sector. ... It’s helmed by geneticist Sir John Bell, who was tasked by the

  • Novo Nordisk invests £115m in Oxford diabetes unit Novo Nordisk invests £115m in Oxford diabetes unit

    Sir John Bell, Oxford University's professor of medicine, said the collaboration will allow for daily interactions between academic and industrial scientists and "underlines the importance of sharing research and

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Pulling together Pulling together

    Responding to these at the end of August saw Sir John Bell publish his ambitious Life Sciences Industrial Strategy report, which offers a wide-ranging plan for making the UK a ... It’s a theme that appears in Sir John Bell’s report, where one of its

  • Pharma deals in March 2015 Pharma deals in March 2015

    Sir John Bell, Regius Professor of Medicine at Oxford University and a non-executive director of Immunocore has criticised the City of London for failing to provide financial support to life

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Shining a light on the true cost of patient care

    When Sir John Bell recently published his recommendations for the Life Sciences strand of the Government’s Industrial Strategy, he said that the NHS’s structure gives it data sharing opportunities ... Sir John’s proposals would involve a major

  • Life at the end of the Brexit tunnel

    Sir John Bell outlined the Life Sciences Industrial Strategy, which includes £160 million of funding to support the health sector, including the NHS. ... As an example of this, Sir John Bell suggested that Artificial Intelligence could be combined with

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics